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Summary There is a heavy burden of HIV—hepatitis B virus (HBV) and HIV—hepatitis C virus
(HCV) co-infection in many regions of the developing world. An often unmentioned illness, issues
of poverty, socio-economic status, nutrition, access to medical care, and mistrust of Western-
style medicine conspire to reduce the opportunity to receive clinical work-up and treatment for
chronic viral hepatitis. We discuss key issues specific to the treatment of viral hepatitis and
obstacles to success with this endeavor in the context of HIV co-infection in Africa. We predict
that provision of viral hepatitis antiviral therapy will become a more pressing issue as more HIV-
infected patients receive lifesaving combination antiretroviral therapy only to succumb there-
after from viral hepatitis-induced liver disease. Given the lessons learned from combination
antiretroviral rollout in sub-Saharan Africa, establishing expertise and infrastructure for viral
hepatitis care and antiviral therapy is relevant. Failure to act now may diminish the milestones
and the gains made with antiretroviral therapy in the developing world.
# 2008 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights
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There is a heavy burden of HIV co-infection with hepatitis B
virus (HBV) and hepatitis C virus (HCV) in many regions of the* Corresponding author. Tel.: +1 613 737 8924; fax: +1 613 737 8164.
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doi:10.1016/j.ijid.2008.06.042developing world.1 Overlapping risk factors for exposure to
these viruses include sex, use of contaminated blood pro-
ducts and needles for medical purposes, injection drug use in
some settings, and tattooing and other cultural skin markings
including traditional surgeries. Issues related to poverty,
socio-economic status, nutrition, access to medical care,
and mistrust of Western-style medicine conspire to reduce
the opportunity to receive clinical work-up and treatment forPublished by Elsevier Ltd. All rights reserved.
Viral hepatitis and HIV in Africa 303chronic viral hepatitis.2 Some experts and decision makers
from the developed world have a nihilistic attitude toward
considering viral hepatitis treatment in those with HIV in the
developing world. This is reminiscent of the recent past when
consideration of broad use of highly active antiretroviral
therapy (HAART) in developing regions was thought to be
naı¨ve, unrealistic, unworkable, and unattainable.3 Although
there are considerable obstacles to providing viral hepatitis
antiviral therapy in the presence of competing priorities,
there will be no hope of ever confronting the consequences
of chronic liver infections without dialogue, contemplation,
preparation, and the acquisition of experience through pilot
programs. Although liver-related death is not currently a
common cause for mortality in those with HIV in developing
regions of the world, this issue may become a more pressing
one. As we have witnessed in the developed world after the
introduction of HAART, we may again observe patients
spared a death from HIV/AIDS only to succumb from the
complications of advanced, untreated viral hepatitis liver
disease.4—6 In this manuscript we focus on key issues specific
to the treatment of viral hepatitis and obstacles to success in
the context of HIV co-infection in developing regions of
Africa.
Burden of disease
The prevalence of chronic viral hepatitis in many regions of
the developing world is uncertain, but estimated to be
approximately 10% for HBV7,8 and to range between 3%
and 20% for HCV.9—12 The incidence and prevalence of viral
hepatitis is heterogeneous and dependant on local practices
either contributing to or diminishing exposure risk.13—15
Routine screening seems justified as a first step to determin-
ing the relative importance of viral hepatitis in HIV in devel-
oping regions of the world.
Reuse of needles for vaccination and other medical pro-
cedures contributes to the current incidence and prevalence
of HBVand HCV infection inmany developing regions.16 This is
best documented in Egypt, where the overall HCV prevalence
rate approaches 20% as a consequence of prior schistosomia-
sis treatment programs.10—12 China, another developing set-
ting, has suffered a series of important public health
catastrophes related to unscreened blood and reuse of nee-
dles.17
In developed regions of the world the blood product supply
is screened sufficiently to diminish HIV and HCV infection risk
to well below 1 per million units.18 In contrast, there are
continuing concerns about blood supply safety in developing
regions. The demand for blood is high in sub-Saharan Africa,
where malaria, pregnancy-related complications, and
trauma necessitate blood product use. Therefore, the con-
tribution of blood product use to the overall prevalence of
HBV and HCV is not trivial. Guidelines that restrict the
unwarranted use of blood products have been implemented
inmany developing regions. Explicit criteria that qualitatively
exclude those at exposure risk to HIV, viral hepatitis, and
syphilis infection are applied. Many testing algorithms for
simultaneous HIV, HBV, and HCV screening use double ELISA
tests with microparticle and microplate technology. Never-
theless, windowperiods during seroconversion remain an issue
of concern given the relatively high incidence of HIV and
limitations of these assays.19 Use of more sensitive bloodscreening equipment is limited by financial resources and
technical support.14
Developing regions highly endemic for HBV often lack
widely implemented HBV vaccination programs. Conse-
quently, these populations are more vulnerable to HBV
infection during childbirth, in early infancy, or at the onset
of sexual activity.20,21 HIV co-infection may further increase
the risk of vertical transmission as HBV viral load is greater
and hepatitis B e antigen seroconversion is delayed.22,23
Both of these factors are important predictors for perinatal
HBV infection risk. HBV screening during pregnancy and
postpartum immunoglobulin and HBV vaccination in neo-
nates born to HBV-infected mothers is far from being uni-
versally implemented.24 Childhood HBV vaccination
programs have achieved remarkable success in reducing
incidence rates of chronic HBV infection in under-resourced
settings.25,26 Broad application of this simple and relatively
inexpensive intervention could reduce HBV and HIV—HBV
co-infection rates.
Regional traditional healing practices and cultural activ-
ities (e.g., cosmetic tattooing, scarification) may influence
the incidence of exposure to HIV, HBV, and HCV.2 Practices
involving blood-to-blood exposure carry with them obvious
risk. Rather than ostracizing traditional healers, we believe
that these individuals may contribute to reducing the inci-
dence of HIV, HBV, and HCV if engaged and educated as to
safe and preventative practices, which they could, in turn,
introduce into their practices.
Injection drug use, the primary mode of HCV exposure in
the developed world, plays little role in the burden of HBVor
HCV infection in most developing regions of Africa. The
socio-cultural and economic environment protects against
the purchase and use of injection drugs and the equipment
needed for their administration. It is plausible that HCV co-
infection rates may actually increase due to economic
development and urbanization, as increased financial
resources will enable individuals to purchase injection drugs
and the required material to inject them. There are devel-
oping regions of the world where drug supply, the required
injection material, and the financial resources, although
meager, are available despite a very low mean monthly
income.27,28 Examples include Eastern India, Burma,
Cambodia, and parts of Thailand. In these regions, injection
drug use contributes to the burden of viral hepatitis infec-
tion.
zHistorically, there has been a substantial burden of liver
cirrhosis and hepatocellular carcinoma, which is primarily a
consequence of highly prevalent chronic viral hepatitis infec-
tion29,30 and aflatoxin hepatotoxicity.31 Obtaining accurate
regional HBV and HCV seroprevalence data in HIV is relevant
given that liver fibrosis rates are accelerated, liver-related
morbidity and mortality increased, and risk of antiretroviral-
related liver complications are greater in those with HIV—viral
hepatitis co-infection.32—34 During the pre-HAART era, viral
hepatitis co-infection was of little concern in the developed
world. However, following broad introduction of antiretroviral
therapy, liver-related disease became and remains a primary
cause of death inHIV-infected patients.4,6 Although these data
come from the developed world, there is little reason to
believe that viral hepatitis behaves differently in developing
regions of the world. As such, the same scenario may unfold
here.
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Although antiretroviral therapy is increasingly available in
many regions of Africa, the supply of drug, the proportion of
patients on treatment, and the presence of expertise to
deliver this therapy falls considerably short of the
need.35—37 That supply of medication will hopefully increase
considerably once a newly approved pharmaceutical factory
in Kampala, Uganda begins production of generic antiretro-
virals.36 Triomune, a combination tablet containing lamivu-
dine, stavudine, and nevirapine, is a staple of antiretroviral
therapy in Africa and is one product that will be produced at
this plant. Production of HBV and HCV antivirals may follow.
The benefits of antiretroviral therapy are clear. However,
the side effects are not inconsequential. Although the true risk
of antiretroviral-related liver toxicity is often overstated, it
can result in interruption of therapy and clinically apparent
signs and symptoms of liver injury.38,39 Knowledge of chronic
viral hepatitis at the individual patient level is relevant as co-
infection does increase the likelihood of antiretroviral-related
liver toxicity. For this reason alone, screening for HBVand HCV
can be justified. Liver toxicity, a term that is nebulous in
meaning, is usually manifested as asymptomatic, self-resol-
ving liver enzyme spikes occurring early after the initiation of
therapy. This occurs in approximately 5% of treatment-naı¨ve
patients.40 Only rarely (1—2%) is clinically relevant liver toxi-
city observed. Irrespective of concurrent viral hepatitis, care-
ful observation of liver function and enzymes is essential.
Given limited laboratory resources this may not be possible
in all locations delivering HIV treatment in developing regions.
A nevirapine reaction consisting of rash and/or liver toxi-
city occurring within the first 16 weeks of therapy is well
described.38,39 This issue is of great relevance in the devel-
oping world given the heavy use of nevirapine in the first-line
treatment of HIV.41 Nevirapine is also recommended for use
during pregnancy to prevent maternal—fetal transmission of
HIV infection. The occurrence of this early nevirapine reac-
tion is not more frequent in viral hepatitis co-infection. It is
noteworthy that after the initial 16 weeks of nevirapine
therapy the occurrence of liver complications is similar to
efavirenz but increased in those with HBV and HCV.42
The incidence of transient liver enzyme increase occurring
with low-dose ritonavir-boosted regimens (100—200 mg daily
or twice daily) is below 5% in treatment-naı¨ve individuals,
between 5% and 10% in treatment-experienced patients, and
similar to that of other protease inhibitor-based HAART regi-
mens.43—51 Fatty liver infiltrate with inflammation and lactic
acidosis are rare but life threatening liver complications of HIV
nucleosidetreatment.52—55This is particularly concerningwith
the use of stavudine and didanosine.52,55 Ribavirin therapy for
HCV indirectly exacerbates this mitochondrial-induced toxi-
city.56 Theuseof stavudine is declining in thedevelopedworld.
In contrast, over 95% of regimens initiated in sub-Saharan
Africa contain stavudine. For multiple reasons, increasing
access to nucleosides characterized by reduced metabolic
toxicity for first-line HAART should be a priority.
Viral hepatitis therapy
In the case of HIV—HBV co-infection, both viruses can be
treated simultaneously with tenofovir and/or lamivudine.HBV monotherapy with these medications is not recom-
mended in HIV—HBV co-infection, as HIV resistance will be
fostered. Oral nucleosides such as telbivudine, which lack HIV
antiviral activity are options for circumstances in which HBV
infection alone requires therapy. Unfortunately, this nucleo-
side is not available for the same reasons HIV therapy was so
long in arriving in Africa: cost, complexity, and lack of
registration.
Successful treatment of HBV in HIV is dependant on
implementation of pre-HAART screening programs for hepa-
titis B surface antigen. Knowledge of HBV co-infection will
result in the selection of appropriate antiretrovirals with dual
antiviral activity, help narrow the differential diagnosis in
treatment recipients developing liver complications while on
HAART, allow for the anticipation of HBV flares when HAART is
interrupted, and increase long-term surveillance for end-
stage liver disease and hepatocellular carcinoma. Screening
for both HIV and HBV will prevent utilization of lamivudine,
tenofovir, or entecavir monotherapy for HBV treatment,
which could result in the evolution of HIV resistance.57
Delivering HCV treatment in the developing world pre-
sents many more challenges. Interferon requires refrigera-
tion that is not universally available. This issue can be
resolved by once weekly directly observed or self-adminis-
tered injections provided by the treatment clinic or outreach
program. These options are available in many regions of
Africa and are already in use for HIV therapy, tuberculosis
treatment, and immunization programs. The decision to
treat HCV (and HBV) is based, at least in part, on liver fibrosis
scores determined by biopsy. In those with little or no
scarring after many years of infection, the likelihood of
future liver dysfunction is minimal. The cost and shear
number of patients in the developing world preclude this
as a reasonable option at the present time. Assuming that the
cost issue can be addressed, FibroTest and other non-invasive
measures of liver fibrosis may help to overcome this hur-
dle.58—60 The need for frequent laboratory checks for safety
monitoring and for several expensive HCV RNA studies prior
to and during HCV therapy is a significant challenge.
Advanced technology for this purpose is available in some
specialized HIV clinics in Africa, but the cost and a need for
expertise in maintaining these instruments represent major
obstacles. This further underscores the need to develop PCR
technology that can be used at the primary care level.61
Although there is no reason to believe that the side effect
profile of HCV therapy would differ in developing region
populations, the consequences of these side effects may
have greater implications. For those on a subsistence income,
any loss of productivity due to medication side effects is
unacceptable. There are few, if any, social support systems
such as medical leave and disability insurance that patients
from developed regions can benefit from.
Conclusion: justification for treatment
At first glance successful implementation of screening, work-
up, and treatment of viral hepatitis in the context of HIV co-
infection may appear unattainable. Current financial condi-
tions preclude treatment in economically underdeveloped
regions of the world. This, of course, was the same argument
forwarded by some to dissuade use of HIV antiretroviral
therapy in these same regions. However, socio-economic
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expertise, and pharmaceutical pricing can change rapidly.
In resource-limited regions, currently available therapy
for HBV and HCV is cost-prohibitive. This issue can be
addressed in several ways. Economic development will
enable some citizens to have greater purchasing power
and allow governments to fund additional health services.
As a first priority, broad HBV vaccine programs should be
implemented as well as HBV screening in those with diag-
nosed HIV infection. In time, viral hepatitis therapy will be
enabled much in the same way that HIV treatment was by
reduced costs for patented HBVand HCV medications and the
allowance of generic production of these medications. This is
already an option for nucleoside/nucleotide HBV therapy.
Interferon and ribavirin are produced generically in India, but
similar facilities do not currently exist in Africa. With the
development of the Cipla factory in Kampala, this may
change. It is noteworthy that Cipla, the Indian generics
company that will own this new Ugandan factory, produces
ribavirin (Ribacip 200). HCV small molecule development
(i.e., HCV protease and polymerase inhibitors) may produce
a next generation of more affordable, better tolerated, and
easier to distribute therapies. However, the many recent
setbacks in HCV drug development suggest that this option
may remain years away.
The cost of not acting on viral hepatitis also needs to be
considered. Hepatocellular carcinoma accounts for a signifi-
cant proportion of all case mortality in Africa.29,30 HBV
antiviral therapy has been demonstrated to reduce the rate
of liver failure and liver carcinoma in HBV mono-infected
individuals.62 Although this has not been clearly demon-
strated to be the same in those with HIV, we and others
speculate that antiviral therapy will accomplish the same
positive outcome.63
In the developed world during the pre-HAARTera, increas-
ing access to HCV antiviral therapy made little sense given
the high morbidity and mortality associated with HIV infec-
tion. Following the introduction of HAART, mortality as a
consequence of HIV rapidly diminished. In contrast, the
proportion of all deaths in HIV-infected patients attributable
to liver-related disease increased and remains a chief cause
of mortality in those living with HIV in the developedworld.4—
6 This same scenario my play out again as HAART becomes
more widely available in developing regions of the world.
Therefore, establishing expertise and infrastructure for viral
hepatitis care and antiviral therapy is relevant. Failure to act
now is likely to result in avoidable morbidity and mortality
later.
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